MAP1LC3A and prostate carcinoma: The SLS expression pattern of LC3A is also strongly correlated with a poor outcome in non-small cell lung carcinoma [47], breast cancer [48], prostate cancer [49], skin squamous cell carcinoma [50], and brain malignancies [51].